Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Family power: exercise and nutrition program may cut surgery complications in stomach cancer

NCT ID NCT07183358

Disease control Sponsor: The Affiliated Hospital of Qingdao University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a family-supervised program combining exercise, nutrition advice, and psychological support can reduce complications after stomach cancer surgery. About 90 adults who will receive chemotherapy before surgery are randomly assigned to either the program plus usual care or usual care alone. The main goal is to see if the program lowers the rate of serious problems like infections or bleeding within 30 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
family-supervised multimodal prehabilitation (exercise, nutrition, and psychological support)
What this could lead to
If it works, this program could help gastric cancer patients recover faster and have fewer serious complications after surgery.
What could go wrong
This is a small, early-stage trial with only 90 participants, so results may not apply to everyone. The program is behavioral, so its benefits depend on patient adherence and family support.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years * Histologically proven gastric adenocarcinoma by gastroscopy * Clinical stage T2-4a, N any, M0 planned for neoadjuvant chemotherapy plus radical gastrectomy * ECOG performance status 0-1; ASA class I-III * Able to understand the study and provide signed informed consent Exclusion Criteria: * Previous or concurrent malignancies * Emergent conditions (bleeding, perforation, obstruction) requiring immediate surgery * Pregnant or lactating women * Severe psychiatric disorders * Prior major abdominal surgery (except laparoscopic cholecystectomy) * Unstable angina, myocardial infarction, or cerebrovascular event within 6 months * Continuous use of NSAIDs, corticosteroids, or probiotics within 1 month * Simultaneous surgery for other diseases * FEV1 \< 50 % predicted * Any condition that, in the investigator's opinion, contraindicates participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoadjuvant therapy Stomach neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Qingdao University Affiliated Hospital

    Qingdao, Shandong, 266003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.